Lutetium Lu 177 Vipivotide Tetraxetan

**Semantic type:** Pharmacologic Substance

**Definition:** A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.

**Synonyms:** - 177Lu-PSMA-617 - 177Lu-labeled PSMA-617 - AAA 617 - AAA-617 - AAA617 - LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - Lu177-PSMA-617 - Lutetium Lu 177 vipivotide tetraxetan - Lutetium Lu 177-PSMA-617 - Lutetium-177-PSMA-617 - Pluvicto